You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Qiagen said that growth in the quarter was primarily driven by COVID-19 testing products and improving customer demand for other products.
JPM moved to an Overweight rating on both companies from a Not Rated designation assigned during a restriction period as Thermo Fisher's potential acquisition of Qiagen played out.
Four diagnostic firms have gone public so far this year, with three of the companies based in China but filing for US initial public offerings.
While new ways to carry out pool testing for SARS-CoV-2 abound, questions remain about sensitivity issues and the regulation of such tests.
Genetron will provide clinical trial genomic testing and companion diagnostic development services for InnoCare's biomarker-driven oncology drug development.
On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.
The startup is exploring options with potential partners and plans to bring a urinary tract infection test through regulatory channels in the next two years.
Biocartis' Idylla called some colorectal cancer samples negative that Sysmex Inostics's OncoBEAM called positive, but the clinical implications may be complex.
The life science segment saw strong sales in Droplet Digital PCR offset by sales the firm's process media product line.
The company's full-year revenues rose 6 percent and were slightly higher than the consensus Wall Street estimate.